Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 17/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | RORB | Q92753 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071932 | 1.00 | RORC (0.64) | RORCALDH1A1FPR1HSD17B10NR1I2 | |
| SCHEMBL15055035 | 1.00 | RORC (0.64) | RORCALDH1A1FPR1HSD17B10NR1I2 | |
| SCHEMBL15054867 | 0.96 | RORC (0.60) | RORCALDH1A1FPR1HSD17B10NR1I2 | |
| SCHEMBL15054990 | 0.96 | RORC (0.60) | RORCALDH1A1FPR1HSD17B10NR1I2 | |
| SCHEMBL28846689 | 0.88 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15130980 | 0.85 | RORC (0.48) | RORCCNR2 | |
| SCHEMBL15078926 | 0.82 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15124035 | 0.82 | RORC (0.65) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15078925 | 0.79 | RORC (0.67) | RORCNR1I2RORANR1H2NR1H3 | |
| SCHEMBL15054951 | 0.79 | RORC (0.67) | RORCNR1I2RORANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150105429-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105429-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105429-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2015-04-16 | — | — | US | disclosed |
| EP-2793873-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20130190356-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190356-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190356-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092939-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092939-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190356-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORC, RORB, RORA | RORC 1/4885ALDH1A1 481/4885FPR1 463/4885 |
| US-20150105429-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORC, RORB, RORA | RORC 1/4885ALDH1A1 481/4885FPR1 463/4885 |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORA, RORC, RORB | RORC 2/4885ALDH1A1 1026/4885FPR1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.